GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com


Jump to: navigation, search


You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki

See Help for Help on this wiki. See the documentation for how to use the table editor


Jacobs, FM, van Erp, S, van der Linden, AJ, von Oerthel, L, Burbach, JP and Smidt, MP (2009) Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development 136:531-40


In recent years, the meso-diencephalic dopaminergic (mdDA) neurons have been extensively studied for their association with Parkinson's disease. Thus far, specification of the dopaminergic phenotype of mdDA neurons is largely attributed to the orphan nuclear receptor Nurr1. In this study, we provide evidence for extensive interplay between Nurr1 and the homeobox transcription factor Pitx3 in vivo. Both Nurr1 and Pitx3 interact with the co-repressor PSF and occupy the promoters of Nurr1 target genes in concert. Moreover, in vivo expression analysis reveals that Nurr1 alone is not sufficient to drive the dopaminergic phenotype in mdDA neurons but requires Pitx3 for full activation of target gene expression. In the absence of Pitx3, Nurr1 is kept in a repressed state through interaction with the co-repressor SMRT. Highly resembling the effect of ligand activation of nuclear receptors, recruitment of Pitx3 modulates the Nurr1 transcriptional complex by decreasing the interaction with SMRT, which acts through HDACs to keep promoters in a repressed deacetylated state. Indeed, interference with HDAC-mediated repression in Pitx3(-/-) embryos efficiently reactivates the expression of Nurr1 target genes, bypassing the necessity for Pitx3. These data position Pitx3 as an essential potentiator of Nurr1 in specifying the dopaminergic phenotype, providing novel insights into mechanisms underlying development of mdDA neurons in vivo, and the programming of stem cells as a future cell replacement therapy for Parkinson's disease.


PubMed Online version:10.1242/dev.029769


Animals; Cell Differentiation; DNA-Binding Proteins/metabolism; Dopamine/metabolism; Embryo, Mammalian/enzymology; Gene Expression Regulation, Developmental; Genome/genetics; Histone Deacetylases/metabolism; Homeodomain Proteins/metabolism; Mice; Models, Biological; Neurons/cytology; Neurons/metabolism; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Subfamily 4, Group A, Member 2; Promoter Regions, Genetic/genetics; Protein Binding; RNA-Binding Proteins/metabolism; Repressor Proteins/metabolism; Transcription Factors/deficiency; Transcription Factors/metabolism